Targeted Oncology

Heather J. Landau, MD (@MSKCancerCenter) discussed the most exciting outcomes observed in a trial of BCMA-targeted NXC-201 for light chain #amyloidosis. 🎥 Watch the full interview: targetedonc.com/view/unique-be…

🔬 A new study shows breast cancers within 3 years postpartum score higher on Oncotype DX, reshaping the risk window and treatment decisions. Read more: targetedonc.com/view/recurrenc… #BreastCancer #Oncology #Medicine

💵 A new study suggests rising out-of-pocket costs push more adults to skip needed care, regardless of cancer history—highlighting financial toxicity and the need for smarter risk screening. Read more: targetedonc.com/view/higher-ou… #CancerCare #Oncology #HealthDisparities

🔬 KEYNOTE-355 posthoc analysis suggests responders can pause chemo yet maintain survival on pembrolizumab; immune adverse effects are mostly mild and manageable. Read more: targetedonc.com/view/early-che… #TNBC #BreastCancer #Immunotherapy #Chemotherapy

🔬 A phase 1 study of actinium (²²⁵Ac) rhPSMA-10.1 injection in patients who have received prior lutetium-177 PSMA-targeted therapy has initiated dosing of patients with metastatic castration-resistant #ProstateCancer. Read more: targetedonc.com/view/first-pat…

🔬 The TRIPLEX trial found thoracic radiotherapy with durvalumab chemo in ES-SCLC adds toxicity and deaths, without boosting survival. 🫁 Read more: targetedonc.com/view/adding-th… #SCLC #LungCancer #SmallCellLungCancer #ThoracicOncology

🔬 SER-155, a multi-strain live biotherapeutic, led to short-term improvement in diarrhea management in patients receiving immune checkpoint inhibitors. Read more: targetedonc.com/view/biotherap… #Immunotherapy #Enterocolitis #Oncology

📢 BREAKING: The #FDA has cleared perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive #BladderCancer, boosting event-free and overall survival ahead of cystectomy. Read more: targetedonc.com/view/fda-appro… #MIBC #GUCancer #FDANews #Oncology

📢 BREAKING: The #FDA has approved subcutaneous isatuximab (Sarclisa Escena) as both manual injection and via an on-body injector (OBI) combined with SOC in multiple #myeloma, based on noninferiority shown in the phase 3 IRAKLIA trial. Read more: targetedonc.com/view/fda-appro…

🔎 FDA News: The #FDA has approved pegfilgrastim-pccg (Ennumo), a biosimilar to Neulasta (pegfilgrastim), to reduce infection from febrile neutropenia in adult and pediatric patients with non-myeloid malignancies. Read more: targetedonc.com/view/fda-appro… #Biosimilar #FDA #Oncology

🔎 FDA News: The #FDA has cleared the IND for UGN-501, an investigational next-gen oncolytic virus. A phase 1 #NMIBC trial is set to test intravesical safety and immune-driven tumor control later this year. Read more: targetedonc.com/view/fda-clear… #BladderCancer #GUCancer

Having shown high responses and manageable safety in phase 1, oral golcadomide + rituximab may enable outpatient care and greater community access for relapsed follicular #lymphoma. 🎥 Daniel Morillo, MD offered his insights at #EHA2026: targetedonc.com/view/golcadomi…

🩺 The PTEN IHC CDx companion diagnostic is now available to determine patients' eligibility for capivasertib in metastatic #ProstateCancer. Read more about the tool and what it could mean for your practice: targetedonc.com/view/diagnosti…

🔬 Ateganosine (THIO) plus cemiplimab shows 90.5% disease control in heavily pretreated #NSCLC in phase 2 THIO-101 trial interim data. Read more: targetedonc.com/view/ateganosi… #LungCancer #ThoracicOncology #ClinicalResearch #CancerTreatment

CELMoD golcadomide plus rituximab showed deep, durable responses in relapsed follicular #lymphoma, with manageable neutropenia and limited added toxicity. Daniel Morillo, MD spoke with us at #EHA2026 to catch us up on the latest data. 🎥 WATCH: targetedonc.com/view/oral-celm…

🔎 FDA News: The #FDA has accepted an NDA for varegacestat, an investigational oral once-daily gamma secretase inhibitor, for the treatment of adults with #DesmoidTumors. 🗓️ The agency assigned a PDUFA target action date of April 28, 2027. Read more: targetedonc.com/view/fda-accep…

💬 Behind every successful bispecific antibody program is months of planning and coordination. Melody Chang, RPh, MBA, BCOP (@AONOncology) explains the work that went into ensuring access to bispecifics across community oncology practices. Read more: targetedonc.com/view/implement…

🎙️ NEW PODCAST EP: Are you keeping up—or just keeping afloat? Dr Pallav Mehta + Drs Yan Ji and Kurt Demel (@_HealthPartners) discuss information overload and where #AI fits into #oncology practice—without replacing clinical judgment. 🎧 Listen: targetedonc.com/view/drowning-…

Peter Voorhees, MD (@LevineCancer) discusses the cost-benefit question of adding pomalidomide to daratumumab and talquetamab in early relapsed multiple #myeloma. 🎥 WATCH: targetedonc.com/view/further-m…

📝 CMS proposes deeper 340B drug payment cuts for hospitals, reshaping outpatient cancer economics, consolidation incentives, and patient cost-sharing. Read more: targetedonc.com/view/cms-propo… #HealthPolicy #HealthEconomics #CancerCare #Oncology